Sell-Off in VIVUS (VVUS) Over Qsymia Patent Concerns is Overdone - Analyst
Go back to Sell-Off in VIVUS (VVUS) Over Qsymia Patent Concerns is Overdone - Analyst| Johnson & Johnson (NYSE: JNJ) | Delayed: 267.37 -6.04 (2.21%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $273.41 | 52 Week High | $126.07 | |||
| Open | $273.40 | 52 Week Low | $94.28 | |||
| Day High | $273.40 | P/E | 55.59 | |||
| Day Low | $267.37 | EPS | $4.81 | |||
| Volume | 6,474,884 | |||||
| Vivus, Inc. (NASDAQ: VVUS) | Delayed: 0.47 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.47 | 52 Week High | $1.85 | |||
| Open | $44.85 | 52 Week Low | $0.92 | |||
| Day High | $0.47 | P/E | N/A | |||
| Day Low | $0.47 | EPS | $-2.13 | |||
| Volume | 1,328 | |||||
